Senate Judiciary Committee Hearing Spotlights Growing Calls for Patent Eligibility Reform
- Jul 20
- 3 min read
America's innovation engine was front and center last week as the Senate Judiciary Committee convened a hearing on patent eligibility and its role in driving breakthroughs across biotechnology, artificial intelligence, diagnostics, and other emerging technologies.
The hearing, From Genes to Machines: the Patent Eligibility Debate, examined whether current patent eligibility standards are providing innovators with the certainty needed to invest in the next generation of discoveries – or whether congressional action is needed to restore clarity.
Ahead of the hearing, We Work For Health submitted comments to the Committee emphasizing that clear, reliable, and predictable patent protections are essential to sustaining American leadership in life sciences innovation. Those themes surfaced repeatedly throughout the discussion, as lawmakers and witnesses examined the impact of patent eligibility uncertainty on investment, competitiveness, and medical progress.
Opening the hearing, Chairman Chuck Grassley (R-Iowa) highlighted the challenge of ensuring that patent law keeps pace with scientific advancement and human ingenuity, describing the debate as one with "tremendous impact on the wellbeing of humanity and the success of our economy."
A recurring theme throughout the hearing was concern that years of court decisions have created uncertainty around what types of inventions are eligible for patent protection.
Sen. Thom Tillis (R-N.C.), a longtime champion of the Patent Eligibility Restoration Act (PERA), argued that the United States risks falling behind global competitors if innovators lack confidence that breakthrough technologies can be protected.
"The world has changed," Tillis said, emphasizing that PERA is not intended to guarantee patents, but to ensure emerging technologies receive fair consideration under U.S. patent law.”
Former U.S. Patent and Trademark Office Director Andrei Iancu echoed those concerns, noting that unclear eligibility standards disproportionately affect startups and small businesses that depend on intellectual property protections to attract investment and bring new products to market.
"Patents may be their principal asset," Iancu testified, arguing that PERA would help restore needed certainty to the innovation ecosystem.
In its submission to the Committee, WWFH warned that uncertainty surrounding patent eligibility is creating challenges for innovators, investors, and researchers working to develop the next generation of technologies and medical treatments. WWFH stressed that patent certainty is particularly important in the life sciences sector, where developing new therapies often requires years of research, substantial investment, and significant risk.
WWFH also highlighted that emerging fields such as gene therapy, precision medicine, diagnostics, and other biotechnology platforms depend on a patent system that gives innovators confidence their inventions can be protected.
At a time when strategic competitors such as China are investing heavily in biotechnology and other advanced technologies – and other jurisdictions, including Europe, continue advancing innovation-friendly patent frameworks – WWFH argued that strengthening patent certainty is critical to maintaining U.S. leadership in innovation.
In its comments to the Committee, WWFH described PERA as an important step toward restoring greater clarity and predictability to patent eligibility law while strengthening America's innovation ecosystem.
For patients, these debates extend well beyond patent law. The ability to attract investment and move promising discoveries through years of research and clinical development can determine whether breakthrough treatments ultimately reach the people who need them.
The hearing concluded with a broader discussion about U.S. competitiveness, with Iancu warning that strengthening the nation's innovation ecosystem is increasingly important in the face of global competition. A reliable intellectual property system, he argued, remains one of the most effective tools for encouraging inventors and investors to build the next generation of breakthroughs in the United States.
As Congress continues to evaluate patent eligibility reform, the hearing highlighted what is at stake: preserving a patent system that gives innovators the confidence to invest, researchers the ability to pursue breakthrough discoveries, and patients access to the next generation of life-saving medicines – while ensuring the United States remains the global leader in biomedical innovation.